Praxis Precision Medicines宣布与FDA达成一致,对Elsunersen在早发Scn2a发育性及癫痫性脑病的注册路径进行简化与加速
Praxis Precision Medicines宣布与FDA达成一致,对Elsunersen在早发Scn2a发育性及癫痫性脑病的注册路径进行简化与加速
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.